Industry News

RespireRx Pharmaceuticals Inc., a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company's President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the BIO Investor Forum on Tuesday, October 18, 2016 at 11:00 A.M. Pacific Time. The Forum is sponsored by the Biotechnology Innovation Organization and is scheduled..."/>
RespireRx Pharmaceuticals Inc. to Present at the BIO Investor Forum on Tuesday, October 18, 2016 at the St. Francis Hotel in San Francisco, California
Fortress Biotech, Inc. company, launched Targadox™ 50 mg film coated tablets indicated as adjunctive therapy for the treatment of severe acne."/>
Journey Medical Corporation Launches Targadox™ Oral Immediate-Release Tablet for Treatment of Severe Acne
Chartwell Retirement Residences announced today a cash distribution of $0.046818 per Trust Unit. The cash distribution will be payable on November 15, 2016 to unitholders of record on October 31, 2016.. Unitholders can participate in Chartwell's Distribution Reinvestment Plan. Eligible investors registered in the DRIP will have their monthly cash distributions used to purchase Trust Units, and will also receive bonus units equal to 3% of their..."/>
Chartwell Retirement Residences Announces October 2016 Distribution
Henry Schein, Inc., the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today its commitment of $50,000 to The American Association of Orthodontists for its Donated Orthodontic Services program. The donation will be made available through Henry Schein Cares, the company's global social responsibility program and Henry Schein Orthodontics, the..."/>
Henry Schein Announces Commitment Of $50,000 Over Five Years To Support The American Association Of Orthodontist's Donated Orthodontic Services Program
Shire plc announces that in results released today from a new national survey, nearly nine in 10 eye care professionals believe our modern, multi-screen lifestyle is responsible for a rise in dry eye disease, and that the condition is becoming increasingly common. While women ages 50 and older are still most likely to be affected by dry eye disease, ECPs also report that use of modern technology is changing the face of the condition, saying..."/>
Multimedia Assets Available: Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease
Allergan plc, a leading global pharmaceutical company, today announced that it has two presentations including a late breaking abstract that will be presented for the first time at the 72 nd American Society of Reproductive Medicine Scientific Congress and Expo in Salt Lake City, Utah, October 15-19.. The scheduled times of the presentations and room locations at the Salt Palace Convention Center are as follows:. "First US-Based Phase 3 Study of..."/>
Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City
PTC Therapeutics, Inc. today provided a regulatory update on Translarna™ for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC Therapeutics announced today that at the end of last week, the Office of Drug Evaluation I of the U.S. Food and Drug Administration denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products on February 22, 2016 regarding PTC's New..."/>
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) for Nonsense Mutation Duchenne Muscular Dystrophy
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative colitis are to be presented at..."/>
Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG
Invacare Corporation announces that it will release its financial results for the third quarter 2016 before the market opens on Monday, October 31, 2016. The company will provide a live conference call and webcast to review its third quarter financial results on Monday, October 31, 2016 at 8:30 AM ET. Investors and other interested parties may access the conference call in the following ways:."/>
Invacare Corporation to Host Conference Call and Webcast to Discuss Third Quarter 2016 Financial Results
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that Samuel R. Chapin has been elected to the Company’ s Board of Directors. "I am pleased to welcome Samuel to our Board, as he brings extensive experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions, along with deep knowledge of the industrial marketplace,” said Robert Friel, Chairman and Chief Executive Officer,..."/>
PerkinElmer Elects Samuel Chapin to Board of Directors
Moleculin Biotech, Inc.,, a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it will host a conference call to discuss important positive developments regarding Annamycin, its drug candidate for the treatment of Acute Myeloid Leukemia, as well..."/>
Moleculin Announces Conference Call to Discuss Positive Developments Regarding Annamycin
Extendicare Inc. announced that it has declared a cash dividend of C $0.04 per common share of the Company for the month of October 2016, which is payable on November 15, 2016 to shareholders of record at the close of business on October 31, 2016. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act. Extendicare has a Dividend Reinvestment Plan, which provides Canadian resident holders of Common Shares with the..."/>
Extendicare Announces October 2016 Dividend of C$0.04 per Share
Teladoc, Inc., the first and largest telehealth platform in the United States, announced that Alan Roga, MD, FACEP, Teladoc senior vice president and general manager, provider market, will participate in the J.P. Morgan Healthcare Banking Group’ s 4th Annual Healthcare Advisory Council."/>
Teladoc Senior Vice President Dr. Alan Roga to Address Hospital and Health System Chief Financial Officers at J.P. Morgan Healthcare Advisory Council
Synergy Pharmaceuticals Inc. today presented new long-term safety data of plecanatide, its investigational, orally-administered compound currently being evaluated by the U.S. Food and Drug Administration for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. These data, which were presented at the American College of Gastroenterology annual scientific meeting, showed that plecanatide was associated with low..."/>
Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of therapies for rare diseases, announced today that the European Medicines Agency has granted orphan designation to exendin 9-39 for the treatment of non-insulinoma pancreatogenous hypoglycemia syndrome. NIPHS describes a spectrum of acquired metabolic disorders characterized by inappropriately high insulin levels and low blood glucose..."/>
Eiger Announces Orphan Designation of Exendin 9-39 for Treatment of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) from European Medicines Agency (EMA)
Mast Therapeutics, Inc. today announced that its wholly-owned subsidiary, Aires Pharmaceuticals, Inc., has entered into a collaborative agreement with Philips Respironics, Inc., the sleep and respiratory care business of Royal Philips related to the supply of Philips' I-neb ® Adaptive Aersol Delivery devices and related consumables for the nebulized delivery of the Company's lead product candidate, AIR001, a sodium nitrite solution for..."/>
Mast Therapeutics Announces Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001
Dextera Surgical Inc., manufacturer of the smallest-profile and most maneuverable articulating surgical stapler platform on the market for minimally invasive surgery, today announced the company has entered into a marketing and distribution agreement with B. Braun Surgical S.A. to bring Dextera’ s MicroCutter 5/ 80 surgical stapler to surgeons in Spain. B. Braun Surgical S.A. is the distribution arm of the B. Braun Aesculap Group headquartered in..."/>
Dextera Surgical Signs Agreement with B. Braun Surgical S.A. for MicroCutter Distribution in Spain
Allergan plc, a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc., a clinical-stage biotechnology company, today announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, has expired with respect to Allergan's pending acquisition of Vitae. The expiration of the HSR waiting period satisfies one of the conditions to the closing of the pending..."/>
Allergan and Vitae Pharmaceuticals Announce Expiration of HSR Waiting Period for Allergan's Proposed Acquisition of Vitae
ConforMIS, Inc., a medical technology company that develops, manufactures and sells joint replacement implants that are customized to fit each patient's unique anatomy, today announced that The Journal of Arthroplasty has accepted for printed publication, and published online, the results of an in vivo clinical study comparing the motion patterns of patients with a ConforMIS iTotal ® CR implant versus patients with a traditional off-the-shelf..."/>
ConforMIS Announces Publication of Clinical Study Demonstrating iTotal CR Customized Implants Better Approximate Normal Knee Motion When Compared to a Leading Off-the-Shelf Total Knee Implant
Lipocine Inc., a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and Drug Administration regarding its New Drug Application for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. The purpose of the meeting was to review the..."/>
Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application
Profound Medical Corp. announced today that it has entered into an agreement with a syndicate of underwriters led by GMP Securities L.P., pursuant to which the Underwriters have agreed to purchase, on a bought deal basis pursuant to the filing of a short form prospectus, 15,820,000 common shares of the..."/>
Profound Medical Corp. Announces $17.4 Million Bought Deal Financing
Five Star Quality Care by ABP Acquisition, an entity controlled by Barry M. Portnoy and Adam D. Portnoy, the company said. Senior Star announced that it intends to commence a tender offer through an affiliated entity for up to 10 million shares of the company's common stock in the coming days at a price of USD3.45 per share in cash and urges FVE..."/>
Senior Star to offer USD3.45 per share for Five Star Quality Care stock

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology476 Articles
Consumer Discretionary366 Articles
Financials339 Articles
Health Care298 Articles
Materials266 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at